T2 Biosystems Announces Presentations at ASM Microbe 2017 Conference

LEXINGTON, Mass., May 24, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced two Industry & Science Showcases during the American Society for Microbiology (ASM) Microbe 2017 Conference in New Orleans, LA., June 1-5. Additionally, there will be several Sessions and Poster Presentations focused on the positive impact of the T2 Magnetic Resonance (T2MR^®) technology by T2 Biosystems and its customers and collaborators. A schedule of all relevant presentations is as follows:

COMPANY INDUSTRY & SCIENCE SHOWCASE: “Application of Rapid, Blood Culture-Free Diagnostics in the Emergency Department: Improving the Signal to Noise Ratio”
Presenters: Dr. Mitchell J. Cohen, M.D., Director of Surgery, Denver Health and the University of Colorado School of Medicine, Denver, CO
Overview: This symposium offers expert guidance on the application of T2MR technology in the Emergency Department setting. Currently in FDA clinical trials, the T2Bacteria Panel identifies bloodstream infection pathogens commonly isolated from patients throughout the hospital, and most often presenting in the Emergency Department. Learn how T2Bacteria may help improve your patient triage, case management and admission processes.
Time: June 2, 1:30-2:15 p.m.
Location: Theater B

COMPANY INDUSTRY & SCIENCE SHOWCASE: “Managing Sepsis in the Golden Hour: Controlling Costs and Improving Patient Care through Diagnostic Testing”
Presenters: Dr. Thomas Kirn, MD, PHD, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, and Dr. Jonathan D. Edwards, Pharm.D., BCPS (AQ-ID), BCGP, Huntsville Hospital, Huntsville, AL
Overview: This symposium will provide a forum for peer-to-peer learning on the proven impact of T2MR technology. This session will review the positive patient care impact and economic benefits realized by using the only FDA-cleared, direct-from-whole-blood assay for the identification of sepsis-causing pathogens, while also discussing products in development that may have a similar impact on healthcare. 
Time: June 4, 12:30 - 1:15 p.m.
Location: Theater B

SESSION:  “Debates in Medical Mycology”
Debate 2:  “Management of Invasive Candidiasis - T2 is the New Standard in Managing IC”
Session Number: #116
Presenter: Samuel L. Aitken, PharmD, BCPS, The University of Texas MD Anderson Cancer Ctr., Houston, TX
Time: June 2, 3:00-5:30 p.m. (Talk 5 scheduled to begin at 4:00 p.m.) 

LATE BREAKER POSTER SESSION: “Assessing High Sensitivity Direct from Blood Pathogen Detection”
Poster Number: #056a
Presented by: T2 Biosystems
Presenting Authors: H. S. Lapp, R. P. Shivers; T2 Biosystems
Time: June 2, 12:45-2:45 p.m.
Location: Exhibit Hall D, Exhibit and Poster Hall

POSTER PRESENTATION: “Clinical Urine Specimens as a Sample Matrix for T2 Magnetic Resonance Technology”
Poster Number: #454
Presented by: Indiana University School of Medicine
Presenting Author:  T. Kieffer, Dept. of Pathology and Lab. Med., Indiana Univ. Sch. of Med.
Time: June 4, 12:15-2:15 p.m.
Location: Exhibit Hall D, Exhibit and Poster Hall

POSTER PRESENTATION: “T2 Magnetic Resonance Technology for the Diagnosis of Candidemia in Low Volume Whole Blood Specimens”
Poster Number: #464
Presented by: Indiana University School of Medicine
Presenting Author: T. Kieffer, Dept. of Pathology and Lab. Med., Indiana Univ. Sch. of Med.
Time: June 4, 12:15-2:15 p.m.
Location: Exhibit Hall D, Exhibit and Poster Hall

POSTER PRESENTATION: “Diagnosis of Fungal Peritonitis Caused by Candida spp. Using T2 Magnetic Resonance Technology on Dialysate Matrix”
Poster Number: #473
Presented by: Indiana University School of Medicine
Presenting Author: T. Kieffer, Dept. of Pathology and Lab. Med., Indiana Univ. Sch. of Med.
Time: June 4, 12:15-2:15 p.m.
Location: Exhibit Hall D, Exhibit and Poster Hall

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx^® Instrument and T2Candida^® Panel targeting sepsis, a life-threatening infection, and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2MR technology to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2017, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
[email protected]
603-553-5803

Media Contact:
Matthew McKillip, T2 Biosystems
[email protected]
518-577-3466

Investor Contact:
Tucker Elcock, Teneo Strategy
[email protected]
212-886-9319